Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 45

1.

Limitation of Infarct Size and No-Reflow by Intracoronary Adenosine Depends Critically on Dose and Duration.

Yetgin T, Uitterdijk A, Te Lintel Hekkert M, Merkus D, Krabbendam-Peters I, van Beusekom HMM, Falotico R, Serruys PW, Manintveld OC, van Geuns RM, Zijlstra F, Duncker DJ.

JACC Cardiovasc Interv. 2015 Dec 28;8(15):1990-1999. doi: 10.1016/j.jcin.2015.08.033.

2.

A nonelutable low-molecular weight heparin stent coating for improved thromboresistance.

Zhao J, Falotico R, Nguyen T, Cheng Y, Parker T, Davé V, Rogers C, Riesenfeld J.

J Biomed Mater Res B Appl Biomater. 2012 Jul;100(5):1274-82. doi: 10.1002/jbm.b.32692. Epub 2012 Mar 27.

PMID:
22454106
3.

Control of cilostazol release kinetics and direction from a stent using a reservoir-based design.

Parker T, Davé V, Falotico R, Zhao J, Nguyen T, He S, Sun YP, Rogers C.

J Biomed Mater Res B Appl Biomater. 2012 Apr;100(3):603-10. doi: 10.1002/jbm.b.31954. Epub 2012 Jan 28.

PMID:
22287299
4.

Morphological and degradation studies of sirolimus-containing poly(lactide-co-glycolide) discs.

Ro AJ, Falotico R, Davé V.

J Biomed Mater Res B Appl Biomater. 2012 Apr;100(3):767-77. doi: 10.1002/jbm.b.32510. Epub 2011 Nov 28.

PMID:
22121085
5.

Microstructure and drug-release studies of sirolimus-containing poly(lactide-co-glycolide) films.

Ro AJ, Falotico R, Davé V.

J Biomed Mater Res B Appl Biomater. 2011 Apr;97(1):30-9. doi: 10.1002/jbm.b.31777. Epub 2011 Feb 2.

PMID:
21290572
6.

Polymers for drug eluting stents.

Parker T, Davé V, Falotico R.

Curr Pharm Des. 2010;16(36):3978-88.

PMID:
21208188
7.

NEVO™: a new generation of sirolimus-eluting coronary stent.

Falotico R, Parker T, Grishaber R, Price S, Cohen SA, Rogers C.

EuroIntervention. 2009 Dec 15;5 Suppl F:F88-93. doi: 10.4244/EIJV5IFA15. No abstract available.

PMID:
22100684
8.

Comparative healing response after sirolimus- and paclitaxel-eluting stent implantation in a pig model of restenosis.

Silva GV, Fernandes MR, Madonna R, Clubb F, Oliveira E, Jimenez-Quevedo P, Branco R, Lopez J, Angeli FS, Sanz-Ruiz R, Vaughn WK, Zheng Y, Baimbridge F, Canales J, Cardoso CO, Assad JA, Falotico R, Perin EC.

Catheter Cardiovasc Interv. 2009 May 1;73(6):801-8. doi: 10.1002/ccd.21879.

PMID:
19309735
9.

Low-dose oral sirolimus reduces atherogenesis, vascular inflammation and modulates plaque composition in mice lacking the LDL receptor.

Zhao L, Ding T, Cyrus T, Cheng Y, Tian H, Ma M, Falotico R, Praticò D.

Br J Pharmacol. 2009 Mar;156(5):774-85. doi: 10.1111/j.1476-5381.2008.00080.x. Epub 2009 Feb 13.

10.

Lipoxygenase and prostaglandin G/H synthase cascades in cardiovascular disease.

Zhao L, Grosser T, Fries S, Kadakia L, Wang H, Zhao J, Falotico R.

Expert Rev Clin Immunol. 2006 Jul;2(4):649-58. doi: 10.1586/1744666X.2.4.649.

PMID:
20477620
11.

Effects of drug combinations on smooth muscle cell proliferation: an isobolographic analysis.

Parry TJ, Thyagarajan R, Argentieri D, Falotico R, Siekierka J, Tallarida RJ.

Eur J Pharmacol. 2006 Feb 17;532(1-2):38-43. Epub 2006 Jan 30.

PMID:
16448648
12.

Drug-eluting stents: sirolimus and paclitaxel differentially affect cultured cells and injured arteries.

Parry TJ, Brosius R, Thyagarajan R, Carter D, Argentieri D, Falotico R, Siekierka J.

Eur J Pharmacol. 2005 Nov 7;524(1-3):19-29. Epub 2005 Nov 3.

PMID:
16271360
13.

Four-year angiographic and intravascular ultrasound follow-up of patients treated with sirolimus-eluting stents.

Sousa JE, Costa MA, Abizaid A, Feres F, Seixas AC, Tanajura LF, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW, Sousa AG.

Circulation. 2005 May 10;111(18):2326-9. Epub 2005 Apr 25.

PMID:
15851603
14.

Long-term effects of polymer-based, slow-release, sirolimus-eluting stents in a porcine coronary model.

Carter AJ, Aggarwal M, Kopia GA, Tio F, Tsao PS, Kolata R, Yeung AC, Llanos G, Dooley J, Falotico R.

Cardiovasc Res. 2004 Sep 1;63(4):617-24.

PMID:
15306217
15.

Update on sirolimus drug-eluting stents.

Kipshidze N, Leon MB, Tsapenko M, Falotico R, Kopia GA, Moses J.

Curr Pharm Des. 2004;10(4):337-48. Review.

PMID:
14965195
16.

Sirolimus-eluting stents: a review of experimental and clinical findings.

Toutouzas K, Di Mario C, Falotico R, Takagi T, Stankovic G, Albiero R, Corvaja N, Colombo A.

Z Kardiol. 2002;91 Suppl 3:49-57. Review.

PMID:
12641015
17.

Two-year angiographic and intravascular ultrasound follow-up after implantation of sirolimus-eluting stents in human coronary arteries.

Sousa JE, Costa MA, Sousa AG, Abizaid AC, Seixas AC, Abizaid AS, Feres F, Mattos LA, Falotico R, Jaeger J, Popma JJ, Serruys PW.

Circulation. 2003 Jan 28;107(3):381-3.

PMID:
12551858
18.

Sirolimus-eluting stent for the treatment of in-stent restenosis: a quantitative coronary angiography and three-dimensional intravascular ultrasound study.

Sousa JE, Costa MA, Abizaid A, Sousa AG, Feres F, Mattos LA, Centemero M, Maldonado G, Abizaid AS, Pinto I, Falotico R, Jaeger J, Popma JJ, Serruys PW.

Circulation. 2003 Jan 7;107(1):24-7.

PMID:
12515737
19.

Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent.

Klugherz BD, Llanos G, Lieuallen W, Kopia GA, Papandreou G, Narayan P, Sasseen B, Adelman SJ, Falotico R, Wilensky RL.

Coron Artery Dis. 2002 May;13(3):183-8.

PMID:
12131023
20.

A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization.

Morice MC, Serruys PW, Sousa JE, Fajadet J, Ban Hayashi E, Perin M, Colombo A, Schuler G, Barragan P, Guagliumi G, Molnàr F, Falotico R; RAVEL Study Group. Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions.

N Engl J Med. 2002 Jun 6;346(23):1773-80.

21.

Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up.

Sousa JE, Costa MA, Abizaid AC, Rensing BJ, Abizaid AS, Tanajura LF, Kozuma K, Van Langenhove G, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW.

Circulation. 2001 Oct 23;104(17):2007-11.

PMID:
11673337
22.

Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model.

Suzuki T, Kopia G, Hayashi S, Bailey LR, Llanos G, Wilensky R, Klugherz BD, Papandreou G, Narayan P, Leon MB, Yeung AC, Tio F, Tsao PS, Falotico R, Carter AJ.

Circulation. 2001 Sep 4;104(10):1188-93.

PMID:
11535578
23.

p27-p16 fusion gene inhibits angioplasty-induced neointimal hyperplasia and coronary artery occlusion.

Tsui LV, Camrud A, Mondesire J, Carlson P, Zayek N, Camrud L, Donahue B, Bauer S, Lin A, Frey D, Rivkin M, Subramanian A, Falotico R, Gyuris J, Schwartz R, McArthur JG.

Circ Res. 2001 Aug 17;89(4):323-8.

PMID:
11509448
24.

Lack of neointimal proliferation after implantation of sirolimus-coated stents in human coronary arteries: a quantitative coronary angiography and three-dimensional intravascular ultrasound study.

Sousa JE, Costa MA, Abizaid A, Abizaid AS, Feres F, Pinto IM, Seixas AC, Staico R, Mattos LA, Sousa AG, Falotico R, Jaeger J, Popma JJ, Serruys PW.

Circulation. 2001 Jan 16;103(2):192-5.

PMID:
11208675
25.

Stability of adenoviral vectors following catheter delivery.

Tsui LV, Zayek N, Frey D, Mello C, Banik G, Falotico R, McArthur JG.

Mol Ther. 2001 Jan;3(1):122-5.

26.

The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit.

Herbert JM, Dol F, Bernat A, Falotico R, Lalé A, Savi P.

Thromb Haemost. 1998 Sep;80(3):512-8.

PMID:
9759636
27.

Cardiovascular actions of thrombin receptor activation in vivo.

Damiano BP, Cheung WM, Mitchell JA, Falotico R.

J Pharmacol Exp Ther. 1996 Dec;279(3):1365-78.

PMID:
8968361
28.

Activation of vascular thrombin receptors mediates cardiac response to alpha-thrombin in isolated, perfused guinea pig heart.

Damiano BP, Mitchell JA, Cheung WM, Falotico R.

Am J Physiol. 1996 May;270(5 Pt 2):H1585-96.

PMID:
8928863
29.

Novel thiazole-based heterocycles as selective inhibitors of fibrinogen-mediated platelet aggregation.

Sanfilippo PJ, Urbanski MJ, Beers KN, Eckardt A, Falotico R, Ginsberg MH, Offord S, Press JB, Tighe J, Tomko K, et al.

J Med Chem. 1995 Jan 6;38(1):34-41.

PMID:
7837237
30.

Cardiovascular profile of RWJ 29009, a new potassium channel activator, in anesthetized and conscious dogs.

Damiano BP, Giardino EC, Haertlein BJ, Stump GL, Mitchell JA, Falotico R.

J Cardiovasc Pharmacol. 1994 Feb;23(2):300-10.

PMID:
7511761
31.

Novel thieno[2,3-b]- and [3,4-b]pyrans as potassium channel openers. Thiophene systems--XVII.

Press JB, McNally JJ, Sanfilippo PJ, Addo MF, Loughney D, Giardino E, Katz LB, Falotico R, Haertlein BJ.

Bioorg Med Chem. 1993 Dec;1(6):423-35.

PMID:
8087564
32.

RWJ 26629, a new potassium channel opener and vascular smooth muscle relaxant: a potential antihypertensive and antianginal agent.

Katz LB, Giardino EC, Salata JJ, Moore JB Jr, Falotico R.

J Pharmacol Exp Ther. 1993 Nov;267(2):648-56.

PMID:
8246137
33.

Synthesis and SAR of 6-substituted purine derivatives as novel selective positive inotropes.

Press JB, Falotico R, Hajos ZG, Sawyers RA, Kanojia RM, Williams L, Haertlein B, Kauffman JA, Lakas-Weiss C, Salata JJ.

J Med Chem. 1992 Nov 27;35(24):4509-15.

PMID:
1335073
34.

Thiophene systems. 14. Synthesis and antihypertensive activity of novel 7-(cyclic amido)-6-hydroxythieno[3,2-b]pyrans and related compounds as new potassium channel activators.

Sanfilippo PJ, McNally JJ, Press JB, Fitzpatrick LJ, Urbanski MJ, Katz LB, Giardino E, Falotico R, Salata J, Moore JB Jr, et al.

J Med Chem. 1992 Nov 13;35(23):4425-33.

PMID:
1447742
35.

Simultaneous monitoring of bemoradan pharmacokinetics and hemodynamics in mongrel dogs.

Huang SM, Falotico R, Haertlein B, Smith IL.

Biopharm Drug Dispos. 1992 Oct;13(7):539-47.

PMID:
1489944
36.

Heteroatom analogues of bemoradan: chemistry and cardiotonic activity of 1,4-benzothiazinylpyridazinones.

Combs DW, Rampulla MS, Demers JP, Falotico R, Moore JB.

J Med Chem. 1992 Jan;35(1):172-6.

PMID:
1732525
37.

6-Benzoxazinylpyridazin-3-ones: potent, long-acting positive inotrope and peripheral vasodilator agents.

Combs DW, Rampulla MS, Bell SC, Klaubert DH, Tobia AJ, Falotico R, Haertlein B, Lakas-Weiss C, Moore JB.

J Med Chem. 1990 Jan;33(1):380-6.

PMID:
2153210
38.

Positive inotropic and hemodynamic properties of flosequinan, a new vasodilator, and a sulfone metabolite.

Falotico R, Haertlein BJ, Lakas-Weiss CS, Salata JJ, Tobia AJ.

J Cardiovasc Pharmacol. 1989 Sep;14(3):412-8.

PMID:
2476620
39.

Renal vasodilators. The role of the 4-substituent in isoquinolin-3-ol cardiovascular agents: 4-ureido derivatives of isoquinolin-3-ol with selective renal vasodilator properties.

Kanojia RM, Lever OW Jr, Press JB, Williams L, Werblood HM, Giardino EC, Falotico R, Tobia AJ.

J Med Chem. 1989 May;32(5):990-7.

PMID:
2709385
40.

Increased vasodilator responsiveness to BRL 34915 in spontaneously hypertensive versus normotensive rats: contrast with nifedipine.

Falotico R, Keiser J, Haertlein B, Cheung WM, Tobia A.

Proc Soc Exp Biol Med. 1989 Feb;190(2):179-85.

PMID:
2915996
41.

Thiophene systems. 9. Thienopyrimidinedione derivatives as potential antihypertensive agents.

Russell RK, Press JB, Rampulla RA, McNally JJ, Falotico R, Keiser JA, Bright DA, Tobia A.

J Med Chem. 1988 Sep;31(9):1786-93.

PMID:
2842504
42.

Cardiotonic agents. Synthesis and inotropic activity of a series of isoquinolin-3-ol derivatives.

Kanojia RM, Press JB, Lever OW Jr, Williams L, McNally JJ, Tobia AJ, Falotico R, Moore JB Jr.

J Med Chem. 1988 Jul;31(7):1363-8.

PMID:
3385731
43.
44.

Inhibition of rabbit platelet phosphodiesterase activity and aggregation by calcium channel blockers.

Moore JB Jr, Fuller BL, Falotico R, Tolman EL.

Thromb Res. 1985 Nov 1;40(3):401-11.

PMID:
2417362
45.

Supplemental Content

Loading ...
Support Center